KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $59.4 million.

  • Amneal Pharmaceuticals' Cash from Financing Activities rose 164.37% to $59.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.6 million, marking a year-over-year increase of 67.14%. This contributed to the annual value of -$211.8 million for FY2024, which is 0.37% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Cash from Financing Activities of $59.4 million as of Q3 2025, which was up 242.59% from -$41.7 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Cash from Financing Activities high stood at $59.4 million for Q3 2025, and its period low was -$100.8 million during Q4 2023.
  • Its 3-year average for Cash from Financing Activities is -$40.5 million, with a median of -$39.2 million in 2025.
  • In the last 5 years, Amneal Pharmaceuticals' Cash from Financing Activities tumbled by 354.87% in 2023 and then soared by 164.37% in 2025.
  • Amneal Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at -$30.4 million in 2021, then increased by 26.96% to -$22.2 million in 2022, then slumped by 354.87% to -$100.8 million in 2023, then spiked by 39.30% to -$61.2 million in 2024, then soared by 164.37% to $59.4 million in 2025.
  • Its Cash from Financing Activities was $59.4 million in Q3 2025, compared to -$41.7 million in Q2 2025 and -$39.2 million in Q1 2025.